PHASE-II STUDY TO EVALUATE ACTIVITY OF DEXRAZOXANE CARDIOXANE IN ORDER TO PREVENT CARDIAC TOXICITY IN PATIENTS WITH BREAST CANCER AND TREATED WITH ANTHRACYCLINE

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-003217-32-IT

Enrollment

Registered

2006-04-21

Start date

2005-11-08

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

To evaluate activity of Dexrazoxane in order to prevent cardiac toxicity in patients with breast cancer and treated with anthracycline MedDRA version: 6.1 Level: PT Classification code 10057654

Interventions

Trade Name: CARDIOXANE IV 1 FL 500 MG Pharmaceutical Form: Powder for infusion* INN or Proposed INN: Dexrazoxane Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 500

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026